涉嫌单位行贿罪，信邦制药被提起公诉

Group 1 - The core issue is that Xinfang Pharmaceutical is facing criminal charges for alleged unit bribery, as indicated by the indictment from the Guizhou Province Kaiyang County People's Court [1] - The company reported a significant decline in both revenue and net profit for 2024, with net profit dropping over 60% year-on-year [2] - In the first three quarters of 2025, the company continued to experience pressure on its performance, achieving revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit of 152.3 million yuan, down 13.74% year-on-year [2] Group 2 - The company has been under scrutiny due to various controversies, including the chairman's divorce and the investigation of its controlling subsidiary and former chairman for bribery [5] - As of January 6, the company's stock price increased by 1.23% to 3.30 yuan per share, with a total market capitalization of approximately 6.415 billion yuan, despite a nearly 30% decline in stock price over the year 2025 [5]